个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Cui, Zhaoqiang[1] ; Qiu, Zhaohui[2] ; Cheng, Wenli[3] ; Hu, Wei[4] ; Ma, Genshan[5] ; Cai, Xiaojun[6] ; Jin, Yafei[7] ; Zhao, Yi[8] ; He, Liqun[9] ; Li, Ying[10] ; Bu, Peili[11] ; Chen, Xiaoping[12] ; Wang, Ruxing[13] ; Chen, Lin[14] ; Dong, Peng[15] ; Feng, Liuliu[16] ; Han, Xuebin[17] ; Hong, Mei[18] ; Hou, Yinglong[19] ; Liao, Minlei[20] ; Wang, Mingliang[21] ; Wang, Xiaoyan[22] ; Xie, Jianhong[23] ; Xu, Yawei[24] ; Wang, Zhenxing[25] ; Huang, Kai[26] ; Li, Yongle[27] ; Li, Dongsheng[28] ; Ji, Xiaojun[29] ; Huang, Jing[30] ; Wang, Jun[31] ; Fang, Danhong[32] ; Wang, Jian'an[33] ; Tang, Lijiang[34] ; Liu, Yingwu[35] ; Fu, Guosheng[36] ; Du, Juan[37] ; Wang, Ling[37] ; Liu, Mengqi[37] ; Ge, Junbo[1,*1] ;
机构： [1]Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai,China [2]Department of Cardiology, Shanghai Tongren Hospital, Shanghai, China [3]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,Beijing, China [4]Department of Cardiology, Central Hospital of Minhang District, Shanghai,China [5]Department of Cardiology, Zhongda Hospital Affiliated to Southeast University,Nanjing, China [6]Department of Cardiology, Jinan Central Hospital, Jinan, China [7]Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China [8]Department of Cardiology, Dalian Jinzhou First People’s Hospital, Dalian, China [9]Department of Cardiology, Wuhan No. 1 Hospital, Wuhan, China [10]Department of Cardiology, Shanghai East Hospital, Shanghai, China [11]Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China [12]Department of Cardiology, West China Hospital of Sichuan University,Chengdu, China [13]Department of Cardiology, Wuxi People’s Hospital, Wuxi, China [14]Department of Cardiology, Third Affiliated Hospital of Sun Yat-Sen University,Guangzhou, China [15]Department of Cardiology, Beijing Aviation General Hospital, Beijing, China [16]Department of Cardiology, Shidong Hospital, Yangpu District, Shanghai, China [17]Department of Cardiology, Shanxi Cardiovascular Hospital (Shanxi Cardiovascular Diseases Institute), Taiyuan, China [18]Department of Cardiology, The Second Clinical Medical College of NanjingMedical University, Nanjing, China [19]Department of Cardiology, The First Affiliated Hospital of Shandong FirstMedical University & Shandong Provincial Qianfoshan Hospital, Jinan, China [20]Department of Cardiology, Baoshan Branch, Shanghai General Hospital,Shanghai, China [21]Department of Cardiology, Putuo People’s Hospital, Tongji University,Shanghai, China [22]Department of Cardiology, Wuxi Third People’s Hospital, Wuxi, China [23]Department of Cardiology, Zhejiang Provincial People’s Hospital, Hangzhou,China [24]Department of Cardiology, Shanghai Tenth People’s Hospital, Shanghai, China [25]Department of Cardiology, Jiangsu Province Hospital of Chinese Medicine,Nanjing, China [26]Department of Cardiology, Union Hospital, Tongji Medical College, HuazhongUniversity of Science and Technology, Wuhan, China [27]Department of Cardiology, Tianjin Medical University General Hospital,Tianjin, China [28]Department of Cardiology, Wuhan Third Hospital, Wuhan, China [29]Department of Cardiology, Wenzhou Central Hospital, Wenzhou, China [30]Department of Cardiology, The Second Affiliated Hospital of ChongqingMedical University, Chongqing, China [31]Department of Cardiology, Jing’an District Central Hospital of Shanghai,Shanghai, China [32]Department of Cardiology, The First Affiliated Hospital of Wenzhou MedicalUniversity, Wenzhou, China [33]Department of Cardiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China [34]Department of Cardiology, Zhejiang Hospital, Hangzhou, China [35]Department of Cardiology, Tianjin Third Central Hospital, Tianjin, China [36]Department of Cardiology, Sir Run Run Shaw Hospital of Zhejiang UniversitySchool of Medicine, Hangzhou, China [37]Medical Department, Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China
出处：
DOI： 10.1111/jch.14700
ISSN：

关键词： adverse events blood pressure target essential hypertension Olmesartan medoxomil-amlodipine besylate tablet satisfaction

摘要：
There lacks real-world study with a large sample size assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM-AML tablet in patients with essential hypertension. Totally, 1341 patients from 36 medical centers with essential hypertension who took OM-AML (20/5 mg) tablet were analyzed in the current prospective, single-arm, multi-center, real-world study (SVK study). Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, week (W)4 and W8 were measured. The mean (& PLUSMN;SE) change of SeSBP/SeDBP was -10.8 & PLUSMN; 0.4/-6.6 & PLUSMN; 0.3 mmHg at W4 and -12.7 & PLUSMN; 0.5/-7.6 & PLUSMN; 0.3 mmHg at W8, respectively. At W4, 78.8% and 29.0% patients achieved BP target by China and American Heart Association (AHA) criteria; at W8, 84.7% and 36.5% patients reached blood pressure (BP) target by China and AHA criteria, accordingly. Meanwhile, 80.2% and 86.4% patients achieved BP response at W4 and W8, respectively. Home-measured SeSBP and SeDBP decreased from W1 to W8 (both p < .001). Besides, patients' and physicians' satisfaction were elevated at W8 compared with W0 (both p < .001). The medication possession rate was 94.8% from baseline to W4 and 91.3% from baseline to W8. The most common drug-related adverse events were nervous system disorders (4.6%), vascular disorders (2.6%), and general disorders and administration site conditions (2.3%) by system organ class, which were generally mild and manageable. In conclusion, OM-AML tablet is one of the best antihypertensive agents in patients with essential hypertension.

基金：
Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 3 区 外周血管病
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 外周血管病
JCR分区：
出版当年[2023]版：
Q2 PERIPHERAL VASCULAR DISEASE
最新[2023]版：
Q2 PERIPHERAL VASCULAR DISEASE

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai,China
通讯作者：
通讯机构： [1]Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai,China [*1]Department of Cardiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.
推荐引用方式(GB/T 7714)：
Cui Zhaoqiang,Qiu Zhaohui,Cheng Wenli,et al.Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study[J].JOURNAL OF CLINICAL HYPERTENSION.2024,26(1):5-16.doi:10.1111/jch.14700.
APA：
Cui, Zhaoqiang,Qiu, Zhaohui,Cheng, Wenli,Hu, Wei,Ma, Genshan...&Ge, Junbo.(2024).Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study.JOURNAL OF CLINICAL HYPERTENSION,26,(1)
MLA：
Cui, Zhaoqiang,et al."Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study".JOURNAL OF CLINICAL HYPERTENSION 26..1(2024):5-16

相关文献

[1]Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study. [2]Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC [3]Individualized prevention of proton pump inhibitor related adverse events by risk stratification [4]38例高血压病患者血脂与胰岛素抵抗 [5]Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer [6]Association of T-cell receptor repertoires and arterial stiffness in patients with essential hypertension [7]Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis [8]Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience. [9]The effect of different administrations of testosterone therapy on adverse prostate events: A Bayesian network meta-analysis [10]Impact of gender on left ventricular deformation in patients with essential hypertension assessed by cardiac magnetic resonance tissue tracking

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号